Stockholm, Sweden – April 21, 2010
Swedish Orphan Biovitrum (STO: BVT) today announced
the results from the second Kiobrina® clinical phase II study. The study demonstrated an improvement in preterm infant growth velocity when Kiobrina® was administered in pasteurized breast milk. As a consequence of this outcome and the previously announced positive results from a phase II study in preterm infant formula, Swedish Orphan Biovitrum has taken the decision to move Kiobrina® into phase III development.

Please, read the whole press release here.